IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study
Authors
Keywords
-
Journal
LANCET
Volume 397, Issue 10284, Pages 1564-1575
Publisher
Elsevier BV
Online
2021-04-23
DOI
10.1016/s0140-6736(21)00440-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
- (2021) Kristian Reich et al. LANCET
- Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
- (2021) Kenneth B Gordon et al. LANCET
- Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
- (2020) Christopher T Ritchlin et al. LANCET
- Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
- (2019) Marie Scully et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin-17A/F Nanobody®, in moderate-to-severe psoriasis
- (2019) Danka Svecova et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The Therapeutic Potential of Nanobodies
- (2019) Ivana Jovčevska et al. BIODRUGS
- Ixekizumab or secukinumab in psoriasis: what difference does it make?
- (2018) C. Paul BRITISH JOURNAL OF DERMATOLOGY
- Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
- (2018) Kim A. Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications
- (2017) Leticia Monin et al. Cold Spring Harbor Perspectives in Biology
- The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor recognition properties
- (2017) Arnaud Goepfert et al. Scientific Reports
- Single-Domain Antibodies As Therapeutics against Human Viral Diseases
- (2017) Yanling Wu et al. Frontiers in Immunology
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials
- (2013) Richard G. B. Langley et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation
- (2013) A. Johnston et al. JOURNAL OF IMMUNOLOGY
- Microbials for the production of monoclonal antibodies and antibody fragments
- (2013) Oliver Spadiut et al. TRENDS IN BIOTECHNOLOGY
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
- (2012) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology
- (2008) B. M. Tijink et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now